E coli Testing Market to Reach $3.9 Billion, Globally, by 2033 at 6.5% CAGR: Allied Market Research
August 06, 2024 08:44 ET
|
Allied Analytics LLP
Wilmington, Delaware , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "E coli Testing Market by Test (Environmental Test, and Clinical Test), and End User...
Dr. Menalee Hapuarachchi Joins Texas Digestive Disease Consultants in Arlington
August 06, 2024 08:15 ET
|
GI Alliance
Arlington, TX, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Texas Digestive Disease Consultants is proud to welcome Dr. Menalee Hapuarachchi, an experienced gastroenterologist who treats all digestive...
STRATA Skin Sciences to Participate in the 9th Annual Virtual Needham MedTech & Diagnostics 1x1 Conference
August 06, 2024 08:15 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and...
Dr. J. Casey Chapman Sheds Light on Gastroparesis for Awareness Month
August 06, 2024 08:10 ET
|
GI Alliance
Dallas, TX, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GI Alliance is proud to highlight the important insights shared by Dr. J. Casey Chapman, a distinguished gastroenterologist and Chief Medical Officer at...
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
August 06, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
High-throughput, high-content imaging-based assay developed to screen convalescent sera for neutralizing antibodies to SARS-CoV-2 variants Study highlights Tonix’s internal R&D...
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
August 06, 2024 08:00 ET
|
Emergent BioSolutions
Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE)...
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis
August 06, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary...
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose...
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
August 06, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 06, 2024 07:30 ET
|
ADC Therapeutics SA
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients...